StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) stock

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$537.79−0.81 (-0.15%)

Close on Nov 16, 2026Market cap $136.31BP/E 31.3Yield –

Vertex Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vertex Pharmaceuticals's price to sales ratio was 11.0× on Nov 11, 2026, against 9.4× a year earlier. Over the last 5 years it ranged from 7.7× to 12.6×, with a median of 9.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202611.0×+1.2
2025Dec 31, 20259.8×+0.1
2024Dec 31, 20249.8×−1.1
2023Dec 29, 202310.9×+2.3
2022Dec 30, 20228.5×+0.6
2021Dec 31, 20217.9×−2.4
2020Dec 31, 202010.3×−5.3
2019Dec 31, 201915.6×+0.6
2018Dec 31, 201815.0×−1.5
2017Dec 29, 201716.5×+5.5
2016Dec 30, 201611.0×−29.7
2015Dec 31, 201540.7×+4.5
2014Dec 31, 201436.3×+21.7
2013Dec 31, 201314.5×+9.4
2012Dec 31, 20125.2×−2.4
2011Dec 30, 20117.6×−56.1
2010Dec 31, 201063.7×+29.4
2009Dec 31, 200934.3×–

More Vertex Pharmaceuticals figures

See a number that looks wrong?